Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31469325 | 0.68 | KDM4E (0.41) | LMNANPC1PKMRECQLRAB9A | |
| SCHEMBL31469377 | 0.68 | TDP2 (0.35) | PDE10AECE1 | |
| SCHEMBL2049587 | 0.68 | PDPK1 (0.33) | PDE10APDPK1SMPD3NPC1PKM | |
| SCHEMBL768868 | 0.67 | SMPD3 (0.42) | PDE10APDPK1SMPD3NPC1PKM | |
| SCHEMBL28154527 | 0.65 | PDPK1 (0.56) | ADORA1ADORA2AADORA3ADORA2BPDPK1 | |
| SCHEMBL25324172 | 0.64 | CSNK1D (0.63) | — | |
| SCHEMBL29957031 | 0.64 | PDPK1 (0.43) | PDPK1SMPD3NPC1RAB9A | |
| SCHEMBL10201578 | 0.63 | HSP90AA1 (0.44) | PDE10APDPK1NPC1PKMRECQL | |
| SCHEMBL953920 | 0.63 | COMT (0.36) | LMNANPC1RAB9A | |
| SCHEMBL8213534 | 0.62 | ESR1 (0.40) | ADORA1ADORA2AADORA3ECE1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| EP-2516441-B1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | Elan Corporation, Inc. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445503-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2516441-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | Elan Pharmaceuticals Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| CN-102762568-A | Pteridinones as inhibitors of polo - like kinase | ELAN PHARM INC | 2012-10-31 | — | — | CN | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079114-A1 | PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | LMNA 2211/4885ADORA1 1980/4885ADORA2A 3335/4885 |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | LMNA 2080/4885ADORA1 2573/4885ADORA2A 3549/4885 |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | PLK1, POLR2E, POLR2H | LMNA 1693/4885ADORA1 2801/4885ADORA2A 3143/4885 |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | LMNA 2130/4885ADORA1 1901/4885ADORA2A 3299/4885 |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | LMNA 2080/4885ADORA1 2573/4885ADORA2A 3549/4885 |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | LMNA 2130/4885ADORA1 1901/4885ADORA2A 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.